We thus speculate that anti-VEGF therapy could lead to improved tumor control when administered to “glucose-addicted” PDX bearing pathogenic and homoplasmic DNA variants due to its effects on nutrients availability, and especially glucose, in the tumor microenvironment. Here, VEGFA is linked to neoplasm.